Adjuvant medical therapy for prostate cancer

Bibliography

• Coleman MP, Quaresma M, Berrino F, Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-56
   PubMed Web of Science ®Google Scholar
• Lughezzani G, Budaus L, Isbarn H, Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy. Eur Urol 2010;57(4):562-8
   PubMedGoogle Scholar
• Fisher B, Carbone P, Economou SG, 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975;292:117-22
   PubMed Web of Science ®Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9
   PubMed Web of Science ®Google Scholar
• Barry MJ, Albertsen PC, Bagshaw MA, Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001;91:2302-14
   PubMed Web of Science ®Google Scholar
• DeFrances CJ, Lucas CA, Buie VC, 2006 National Hospital Discharge Survey. Natl Health Stat Report 2008;30(5):1-20
   Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Gerber GS, Thisted RA, Chodak GW, Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997;32:385-90
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956-62
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collette L, Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572-8
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U, Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924-30
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Sarosdy M, Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472-9
   PubMed Web of Science ®Google Scholar
• Flaig TW, Nordeen SK, Lucia MS, Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol 2007;177:1229-37
   PubMed Web of Science ®Google Scholar
• Whittemore DE, Hick EJ, Carter MR, Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. J Urol 2008;179:516-22
   PubMed Web of Science ®Google Scholar
• Nanda A, Chen MH, Renshaw AA, Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009;74:1419-23
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Epstein JI, Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406
   PubMed Web of Science ®Google Scholar
• O'Brien MF, Cronin AM, Fearn PA, Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591-7
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Kattan MW, Eastham JA, Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-5
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Eastham JA, Graefen M, Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 2005;66:1245-50
   PubMed Web of Science ®Google Scholar
• Klein EA, Bianco FJ, Serio AM, Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008;179:2212-16
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168-72
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Malkowicz SB, Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001;166:2185-8
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71
   PubMed Web of Science ®Google Scholar
• Kattan MW, Vickers AJ, Yu C, Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009;115:1005-10
   PubMedGoogle Scholar
• Roach III M, Waldman F, Pollack A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009;115:3112-20
   PubMedGoogle Scholar
• Shaffer DR, Leversha MA, Danila DC, Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-9
   PubMed Web of Science ®Google Scholar
• de Bono JS, Scher HI, Montgomery RB, Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9
   PubMed Web of Science ®Google Scholar
• Stott SL, Lee RJ, Nagrath S, Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010;2(25):25ra23
   Google Scholar
• Chrisp P, Goa KL. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs 1991;41:254-88
   PubMedGoogle Scholar
• Mahler C, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998;34:405-17
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-8
   PubMed Web of Science ®Google Scholar
• Granfors T, Modig H, Damber JE, Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998;159:2030-4
   PubMedGoogle Scholar
• Granfors T, Modig H, Damber JE, Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006;176:544-7
   PubMed Web of Science ®Google Scholar
• Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother 2008;9:2829-41
   PubMed Web of Science ®Google Scholar
• Levine GN, D'Amico AV, Berger P, Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010;60(3):194-201
   PubMedGoogle Scholar
• Studer UE, Whelan P, Albrecht W, Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868-76
   PubMed Web of Science ®Google Scholar
• Zincke H, Bergstralh EJ, Larson-Keller JJ, Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992;70:311-23
   PubMed Web of Science ®Google Scholar
• Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998;159:357-64
   PubMed Web of Science ®Google Scholar
• Wirth MP, Weissbach L, Marx FJ, Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70
   PubMed Web of Science ®Google Scholar
• McLeod DG, Iversen P, See WA, Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247-54
   PubMed Web of Science ®Google Scholar
• Aus G, Abrahamsson PA, Ahlgren G, Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 2002;90:561-6
   PubMed Web of Science ®Google Scholar
• Soloway MS, Sharifi R, Wajsman Z, Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424-8
   PubMed Web of Science ®Google Scholar
• Schulman CC, Debruyne FM, Forster G, 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 2000;38:706-13
   PubMed Web of Science ®Google Scholar
• Gleave ME, Goldenberg SL, Chin JL, Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001;166:500-6; discussion 506-7
   PubMed Web of Science ®Google Scholar
• Selli C, Montironi R, Bono A, Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol 2002;55:508-13
   PubMed Web of Science ®Google Scholar
• Radiation Therapy Oncology Group; National Cancer Institute; Southwest Oncology Group. Radiation therapy with or without bicalutamide in treating patients with stage II, stage III, or recurrent prostate cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00002874 NLM Identifier: NCT00002874 [Cited 7 July 2010]
   Google Scholar
• National Cancer Institute; Cancer and Leukemia Group B. Prostate Radiation therapy or short-term androgen deprivation therapy and pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00567580 NLM Identifier: NCT00567580 [Cited 7 July 2010]
   Google Scholar
• Medical Research Council. Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00541047 NLM Identifier: NCT00541047 [Cited 7 July 2010]
   Google Scholar
• Roach III M, Bae K, Speight J, Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585-91
   PubMedGoogle Scholar
• Pilepich MV, Krall JM, al-Sarraf M, Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-23
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-90
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L, Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-6
   PubMed Web of Science ®Google Scholar
• Hanks GE, Pajak TF, Porter A, Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Bae K, Hanks GE, Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497-504
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8
   PubMed Web of Science ®Google Scholar
• Tyrrell CJ, Payne H, See WA, Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother Oncol 2005;76:4-10
   PubMedGoogle Scholar
• See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin Oncol 2006;132(Suppl 1):S7-16
   PubMedGoogle Scholar
• Kumar S, Shelley M, Harrison C, Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019
   PubMedGoogle Scholar
• Zelefsky MJ, Eastham JA, Cronin AM, Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010;28(9):1508-13
   PubMedGoogle Scholar
• Schmidt JD, Gibbons RP, Murphy GP, Adjuvant therapy for localized prostate cancer. Cancer 1993;71:1005-13
   PubMed Web of Science ®Google Scholar
• Murphy GP, Beckley S, Brady MF, Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51:1264-72
   PubMedGoogle Scholar
• Tannock IF, Osoba D, Stockler MR, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64
   PubMed Web of Science ®Google Scholar
• Wang J, Halford S, Rigg A, Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675-80
   PubMed Web of Science ®Google Scholar
• Flaig TW, Tangen CM, Hussain MH, Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008;26:1532-6
   PubMed Web of Science ®Google Scholar
• Glode LM, Tangen CM, Hussain MH, Thompson: Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. J Clin Oncol 2009;27(Suppl): abstract 5009
   Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis. Adjuvant leuprolide with or without docetaxel in high risk prostate cancer after radical prostatectomy. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00283062 NLM Identifier: NCT00283062 [Cited 7 July 2010]
   Google Scholar
• Cancer and Leukemia Group B; National Cancer Institute; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group. Surgery with or without docetaxel and leuprolide or goserelin in treating patients with high-risk localized prostate cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00430183 NLM Identifier: NCT00430183 [Cited 7 July 2010]
   Google Scholar
• Department of Veterans Affairs; Sanofi-Aventis. Chemotherapy after prostatectomy (CAP) for High risk prostate carcinoma. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00132301 NLM Identifier: NCT00132301 [Cited 7 July 2010]
   Google Scholar
• Radiation Therapy Oncology Group; National Cancer Institute. Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00288080 NLM Identifier: NCT00288080 [Cited 4 August 2010]
   Google Scholar
• Dreicer R, Magi-Galluzzi C, Zhou M, Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138-42
   PubMed Web of Science ®Google Scholar
• Febbo PG, Richie JP, George DJ, Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40
   PubMed Web of Science ®Google Scholar
• Chi KN, Chin JL, Winquist E, Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180:565-70; discussion 570
   PubMed Web of Science ®Google Scholar
• Federation Nationale des Centres de Lutte Contre le Cancer. Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000. Available from: http://clinicaltrials.gov/ct2/show/NCT00055731 NLM Identifier: NCT00055731 [Cited 7 July 2010]
   Google Scholar